Literature DB >> 11479506

Pathologic N0 status in pulmonary adenocarcinoma is predictable by combining serum carcinoembryonic antigen level and computed tomographic findings.

K Takamochi1, K Nagai, J Yoshida, K Suzuki, Y Ohde, M Nishimura, S Sasaki, Y Nishiwaki.   

Abstract

OBJECTIVES: It is not clear whether lymphadenectomy has therapeutic benefit in non-small cell lung cancer management. To avoid unnecessary lymphadenectomy, we attempted to identify clinical or radiologic predictors of pathologic N0 disease in patients with peripheral adenocarcinoma.
METHODS: From August 1992 through April 1997, 269 consecutive patients with peripheral adenocarcinoma who underwent major lung resection and systematic lymph node dissection were enrolled in this study. We reviewed their contrast-enhancement computed tomographic scans and recorded the maximum dimension of tumors both on pulmonary (pDmax) and on mediastinal (mDmax) window setting images, the largest dimension perpendicular to the maximum axis on both pulmonary (pDperp) and mediastinal (mDperp) window setting images, and the size of all detectable hilar-mediastinal lymph nodes. We defined a new radiologic parameter, tumor shadow disappearance rate (TDR), which is calculated with the following formula: TDR = 1 - (mDmax x mDperp)/(pDmax x pDperp).
RESULTS: In multivariable analysis a lower serum carcinoembryonic antigen level and a higher tumor shadow disappearance rate were significant predictors of pathologic N0 disease. Lymph node size on computed tomographic scanning was not a significant predictor. Among 59 patients with a normal preoperative carcinoembryonic antigen level and a tumor shadow disappearance rate of 0.8 or more, 58 (98%) patients had pathologic N0 disease, and the other patient had pathologic N1 disease.
CONCLUSIONS: Mediastinal lymph node involvement was not found in patients with a normal preoperative serum carcinoembryonic antigen level and a tumor shadow disappearance rate 0.8 or more. The patients who meet these criteria may be successfully managed with major lung resection without systematic mediastinal lymphadenectomy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479506     DOI: 10.1067/mtc.2001.114355

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  31 in total

1.  Radiologic and nuclear medicine predictors of tumor invasiveness in patients with clinical stage IA lung adenocarcinoma.

Authors:  Masaya Tamura; Makoto Oda; Isao Matsumoto; Yosuke Shimizu; Ryuichi Waseda; Go Watanabe
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

2.  Prediction of pathological nodal involvement by CT-based Radiomic features of the primary tumor in patients with clinically node-negative peripheral lung adenocarcinomas.

Authors:  Ying Liu; Jongphil Kim; Yoganand Balagurunathan; Samuel Hawkins; Olya Stringfield; Matthew B Schabath; Qian Li; Fangyuan Qu; Shichang Liu; Alberto L Garcia; Zhaoxiang Ye; Robert J Gillies
Journal:  Med Phys       Date:  2018-04-29       Impact factor: 4.071

Review 3.  Whack-a-mole strategy for multifocal ground glass opacities of the lung.

Authors:  Kenji Suzuki
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

4.  Detection and quantification of the solid component in pulmonary subsolid nodules by semiautomatic segmentation.

Authors:  Ernst Th Scholten; Colin Jacobs; Bram van Ginneken; Sarah van Riel; Rozemarijn Vliegenthart; Matthijs Oudkerk; Harry J de Koning; Nanda Horeweg; Mathias Prokop; Hester A Gietema; Willem P Th M Mali; Pim A de Jong
Journal:  Eur Radiol       Date:  2014-10-07       Impact factor: 5.315

5.  Can image analysis on high-resolution computed tomography predict non-invasive growth in adenocarcinoma of the lung?

Authors:  Yukihiro Yoshida; Miki Sakamoto; Eriko Maeda; Hiroshi Ohtsu; Satoshi Ota; Hisao Asamura; Jun Nakajima
Journal:  Ann Thorac Cardiovasc Surg       Date:  2014-04-18       Impact factor: 1.520

Review 6.  The lung adenocarcinoma guidelines: what to be considered by surgeons.

Authors:  Rodrigo A S Sardenberg; Evandro Sobroza Mello; Riad N Younes
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

7.  Comparison of a radiomic biomarker with volumetric analysis for decoding tumour phenotypes of lung adenocarcinoma with different disease-specific survival.

Authors:  Mei Yuan; Yu-Dong Zhang; Xue-Hui Pu; Yan Zhong; Hai Li; Jiang-Fen Wu; Tong-Fu Yu
Journal:  Eur Radiol       Date:  2017-05-18       Impact factor: 5.315

8.  Computer-Aided Nodule Assessment and Risk Yield Risk Management of Adenocarcinoma: The Future of Imaging?

Authors:  Finbar Foley; Srinivasan Rajagopalan; Sushravya M Raghunath; Jennifer M Boland; Ronald A Karwoski; Fabien Maldonado; Brian J Bartholmai; Tobias Peikert
Journal:  Semin Thorac Cardiovasc Surg       Date:  2016-01-08

9.  Lung cancer with scattered consolidation: detection of new independent radiological category of peripheral lung cancer on thin-section computed tomography.

Authors:  Takeshi Matsunaga; Kenji Suzuki; Aritoshi Hattori; Mariko Fukui; Yoshitaka Kitamura; Yoshikazu Miyasaka; Kazuya Takamochi; Shiaki Oh
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-12-17

10.  Thin-section computed tomography findings of lung adenocarcinoma with inherent metastatic potential.

Authors:  Shigeki Suzuki; Keiju Aokage; Junji Yoshida; Genichiro Ishii; Yuki Matsumura; Tomohiro Haruki; Tomoyuki Hishida; Kanji Nagai
Journal:  Surg Today       Date:  2016-09-22       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.